Notice: This company has been marked as potentially delisted and may not be actively trading. Sierra Oncology (SRRA) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Sierra Space eyes IPO market as it braces for a 'profound industrial revolution' in spaceApril 11, 2024 | msn.comSierra Oncology Inc.February 21, 2024 | thestreet.comSierra Coupon for OctoberNovember 9, 2023 | time.comFDA approves GSK's unique myelofibrosis treatment OjjaaraSeptember 18, 2023 | msn.comPleasant Surprise For GSK: FDA Approves Bone Marrow Cancer Therapy Acquired Via Sierra Oncology DealSeptember 18, 2023 | msn.comFDA approves GSK's Ojjaara for treatment of myelofibrosis-related anaemiaSeptember 18, 2023 | msn.comAnalyst calls of the week: Palo Alto upped, Carnival earnings preview and moreJune 16, 2023 | proactiveinvestors.comSierra Oncology (NASDAQ: SRRA)June 12, 2023 | fool.comCelyad Oncology Stock (NASDAQ:CYAD), Quotes and News SummaryFebruary 25, 2023 | benzinga.comSierra LeoneFebruary 22, 2023 | bbc.co.ukInterventional Oncology Global Market - Forecast To 2029January 20, 2023 | finance.yahoo.comGSK Signs Deal to Develop Antibodies for Treating CancerJanuary 5, 2023 | nasdaq.comSareum Holdings Says Sierra Oncology To Return Cancer Treatment License; Shares FallOctober 12, 2022 | marketwatch.comCompanion Diagnostic Tests in Oncology Market 2022 Key Product Segments, Application Analysis, and Industry Growth Forecast by 2027September 25, 2022 | marketwatch.com15 Biotech Firms That Have Strong Potential to Be Acquired: JefferiesSeptember 1, 2022 | thestreet.comSierra Leone passes new laws to boost landowners' rightsAugust 8, 2022 | yahoo.comSareum Holdings Says GSK Completes Acquisition of Sierra OncologyJuly 4, 2022 | marketwatch.comTrading was temporarily halted for "SRRA" at 07:06 PM with a stated reason of "News pending."July 1, 2022 | marketbeat.comSierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug AdministrationJune 17, 2022 | finance.yahoo.comSierra Oncology hits 52w high – but will it continue?June 13, 2022 | uk.finance.yahoo.comSierra Oncology, Inc. (NASDAQ:SRRA) Given Consensus Rating of "Hold" by BrokeragesShares of Sierra Oncology, Inc. (NASDAQ:SRRA - Get Rating) have received an average rating of "Hold" from the six brokerages that are covering the firm, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the companyJune 3, 2022 | marketbeat.comMomelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual MeetingMay 26, 2022 | finance.yahoo.com-$0.95 Earnings Per Share Expected for Sierra Oncology, Inc. (NASDAQ:SRRA) This QuarterEquities research analysts forecast that Sierra Oncology, Inc. (NASDAQ:SRRA - Get Rating) will announce earnings of ($0.95) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Sierra Oncology's earnings, with the highest EPS estimate cMay 22, 2022 | marketbeat.comSierra Oncology (NASDAQ:SRRA) Downgraded to Hold at Zacks Investment ResearchZacks Investment Research cut Sierra Oncology from a "buy" rating to a "hold" rating in a research note on Wednesday.May 18, 2022 | marketbeat.comShort Interest in Sierra Oncology, Inc. (NASDAQ:SRRA) Decreases By 55.9%Sierra Oncology, Inc. (NASDAQ:SRRA - Get Rating) saw a large decline in short interest in the month of April. As of April 30th, there was short interest totalling 1,010,000 shares, a decline of 55.9% from the April 15th total of 2,290,000 shares. Based on an average daily volume of 595,100 shares, the days-to-cover ratio is currently 1.7 days.May 13, 2022 | marketbeat.comSierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual MeetingMay 12, 2022 | finance.yahoo.comSierra Oncology, Inc. (NASDAQ:SRRA) Receives Consensus Rating of "Hold" from AnalystsSierra Oncology, Inc. (NASDAQ:SRRA - Get Rating) has been assigned a consensus rating of "Hold" from the six ratings firms that are covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the cMay 9, 2022 | marketbeat.comSierra Oncology Reports First Quarter 2022 ResultsMay 6, 2022 | finance.yahoo.comSIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRAMay 2, 2022 | stockhouse.comBiotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & MoreApril 14, 2022 | msn.comAnalyzing Sierra Oncology Inc's Short InterestApril 14, 2022 | msn.comAnalyst Ratings for Sierra OncologyApril 14, 2022 | markets.businessinsider.comSHAREHOLDER ALERT: Weiss Law Investigates Sierra Oncology, Inc.April 13, 2022 | prnewswire.comGlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash DealApril 13, 2022 | finance.yahoo.comSierra Oncology Stock Is Soaring: Here's WhyApril 13, 2022 | markets.businessinsider.comWhy Is Sierra Oncology (SRRA) Stock Up Today?April 13, 2022 | investorplace.comGlaxoSmithKline to buy Sierra Oncology for $1.9 billionApril 13, 2022 | msn.comGSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bnApril 13, 2022 | finance.yahoo.comGSK Agrees To Acquire Sierra Oncology For $1.9 BlnApril 13, 2022 | nasdaq.comSRRA Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Sierra Oncology, Inc. Is Fair to ShareholdersApril 13, 2022 | tmcnet.comGSK to buy Sierra Oncology for $1.9 bln in boost to blood cancer opsApril 13, 2022 | reuters.comSierra Oncology Stock Soars After $1.9 Billion Takeover by GlaxoSmithKlineApril 13, 2022 | barrons.comSierra Oncology Stock Soars After $1.9 Billion Takeover by GlaxoApril 13, 2022 | finance.yahoo.comBiotech Feeding Spree As GSK, Halozyme Announce Nearly $3 Billion In DealsApril 13, 2022 | finance.yahoo.comOppenheimer Increases Sierra Oncology (NASDAQ:SRRA) Price Target to $45.00Oppenheimer upped their price objective on shares of Sierra Oncology from $38.00 to $45.00 in a report on Monday.March 14, 2022 | marketbeat.comSierra Oncology Non-GAAP EPS of -$1.44March 11, 2022 | seekingalpha.comSierra Oncology Reports 2021 Year End ResultsMarch 10, 2022 | finance.yahoo.comHarley-Davidson, SOC Telemed Stocks See Action From Activist InvestorsFebruary 12, 2022 | finance.yahoo.comSierra Oncology raises additional funds from underwriters of stock offeringFebruary 3, 2022 | seekingalpha.comSierra Oncology Announces Full Exercise of Underwriters’ Option to Purchase Additional SharesFebruary 3, 2022 | finance.yahoo.com Get Sierra Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for SRRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Vladimir Lenin was right… (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier. Including the name of the #1 company to buy. SRRA Media Mentions By Week SRRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SRRA News Sentiment▼0.000.60▲Average Medical News Sentiment SRRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SRRA Articles This Week▼00▲SRRA Articles Average Week Get Sierra Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for SRRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TG Therapeutics News Viking Therapeutics News BridgeBio Pharma News Grifols News Crinetics Pharmaceuticals News Alkermes News Axsome Therapeutics News Ultragenyx Pharmaceutical News Biohaven News Apellis Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SRRA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sierra Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sierra Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
